Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
?CytomX Therapeutics, Inc,this week?Pfizer Inc.?notified the Bay Area-based company of its?intent to terminate?its five-year-old oncology collaboration.